Close Menu

NEW YORK (GenomeWeb) – Transgenomic said after the close of the market on Friday that its second quarter sales revenues rose slightly year over year.

For the three months ended June 30, the firm reported revenues of $505,000 compared to $442,000 in the year-ago quarter.

The company's laboratory services revenues were flat year over year, with the slight increase in total revenues due to oncology revenues and awarded grants.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.